TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01659307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 75mg
Description: Subjects randomised to aspirin 75mg will receive 1 container containing aspirin 75mg and 1 container containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose powder
Description: Subjects randomised to placebo will receive 4 containers of placebo, 2 containers containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 1200mg
Description: Subjects randomised to aspirin 600mg 12 hourly will receive 2 containers of aspirin 300mg each for the morning and 2 containers of aspirin 300mg each for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
Study: NCT03716141

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Platelets Rich Plasma Treatment
Description: For PRP preparation 10 mL of the patient blood was collected. The blood was centrifuged at 2000 rpm for 5 min to obtain plasma. Then, this plasma was centrifuged at 3000 rpm for another 5 min to collect platelets. Platelets were diluted in 5 mL plasma to form PRP.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Saline dressing
Description: saline dressing of diabetic wounds will be done
Study: NCT03914066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A group-based treatment of overweight and obesity
Description: The intervention is a group treatment of overweight and obesity in primary care inspired by cognitive behavioural therapy. The main goal of the group treatment is for the participants to obtain and maintain healthy lifestyle habits, with emphasis on diet and physical activity. Every group has 8-12 participants and is led by two persons; the main group leader is either a primary care nurse or a physiotherapist with special training. The groups meet six times (2 hours every time) once a month over a 6-8 month period. Every group session has a set agenda with different topics, for example a healthy diet, recommended physical activity or how to deal with setbacks. Between group sessions there are home assignments. The home assignments are followed-up at the next session and participants are encouraged to share experiences with each other in order to inspire, challenge and help fellow group participants. Data is collected prior to the start of group treatment, after 6-8 and 12 months.
Study: NCT02567838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine gel
Description: Instillagel (2% lidocaine) was administered rectally prior to probe insertion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Aquagel) was administered rectally prior to probe insertion.
Study: NCT04113239

Intervention type: DIAGNOSTIC_TEST
Intervention: 16S rRNA gene sequencing
Description: Taking a stool sample for gut microbiome DNA sequencing

Intervention type: DIAGNOSTIC_TEST
Intervention: 16S rRNA gene sequencing
Description: Taking a stool sample for gut microbiome DNA sequencing

Intervention type: GENETIC
Intervention: DNA-microarray genotyping
Description: Taking a saliva sample for genotyping

Intervention type: GENETIC
Intervention: DNA-microarray genotyping
Description: Taking a saliva sample for genotyping
Study: NCT01520857

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transabdominal Preperitoneal repair of inguinal hernia
Description: Transabdominal Preperitoneal (TAPP) repair of inguinal hernia using CO2 pneumoperitoneum under spinal anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transabdominal Preperitoneal repair of inguinal hernia
Description: Transabdominal Preperitoneal (TAPP) repair of inguinal hernia using CO2 pneumoperitoneum under general anesthesia
Study: NCT03270293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Profhilo
Study: NCT01056770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: smallpox vaccine CJ-50300
Description: Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
Study: NCT03106610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg of body weight by vein over about 60 minutes on Day 1 of Cycles 1-3.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: 2 quality-of-life questionnaires completed on Day 1 of Cycles 1-3, at the visit before surgery, and 4 weeks after surgery.
Study: NCT03140007

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: single operator cholangioscopy
Description: If patient is randomized to the Study arm, then the procedure will consist of the following in order: Cannulation and sphincterotomy per standard of practice. POCS with recording of POCS-based impression of malignancy (yes/no/indeterminate). POCS will be performed using the Spy DS system. POCS-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The POCS-guided biopsy forceps will be the SpyBite forceps.

Intervention type: DEVICE
Group type: OTHER
Intervention: ERCP guided brushing and biopsy
Description: • If patients are randomized to the Control arm, then they will undergo an ERCP. ERCP-based impression of malignancy (yes/no/indeterminate) will be recorded. ERCP-guided brushing and ERCP-guided biopsy will be performed.
Study: NCT03119480

Intervention type: DEVICE
Intervention: electronic alerts
Description: electronic alerts for AKI
Study: NCT02989688

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nepro HP (Abbott Nutrition)
Description: oral nutritional supplement drink with modified carbohydrate composition

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortisip compact protein 125 ml + Calogen 20ml (Nutricia)
Description: Fortisip compact protein 125 ml + Calogen 20ml (Nutricia) oral nutritional supplement drink macronutrient matched with standard carbohydrate composition

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortisip compact 125 ml (Nutricia)
Description: Fortisip compact 125 ml (Nutricia) oral nutritional supplement drink - standard
Study: NCT03657160

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab Placebo
Description: Vedolizumab placebo-matching IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV infusion.
Study: NCT02572921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychotherapy
Description: The Positive Psychotherapy Group Treatment was developed by Martin Seligman and Tayyab Rashid (2013) and consists of 14 weekly group sessions of 2 hours. The strictly manualized program includes the following components:~positive orientation and introduction, character strengths, signature strengths, good vs. bad memories, forgiveness, gratitude, satisficing vs. maximising, meaningful life, posttraumatic growth, hope and optimism, positive communication, signature strengths of others, savouring and slowness, altruism and the last session is about the integration of all these components to the full life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: This well-established, cognitive-behavior group therapy was developed by Schaub, Roth and Goldmann (2006) and consists of 12 weekly group sessions of 2 hours. The strictly manualized program includes the following components: education, building up activities, cognitive restructuring, relapse prevention. Moreover, there are 2 sessions added to the standard program: one session concerning savouring and the other one concerning stress reduction. Thus the whole program consists of 14 sessions.
Study: NCT00973193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: intravenous infusion of panitumumab, 6 mg per kg body weight, once every 14 days for a total of 42 days
Study: NCT02183571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merck Glucophage® high dose
Description: Part I: Treatment A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS Glucophage® high dose
Description: Part I: Treatment B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merck Glucophage® low dose
Description: Part II: Treatment C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS Glucophage® low dose
Description: Part II: Treatment D
Study: NCT01184560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine
Description: ○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~* Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~* Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sibutramine
Description: ○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~* Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~* Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: ○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~* Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~* Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Orlistat
Description: ○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~* Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~* Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily
Study: NCT04403880

Intervention type: OTHER
Intervention: Sample collection
Description: * Optional nasal specimen(s)~* Blood collection

Intervention type: OTHER
Intervention: Sample collection
Description: * Optional nasal specimen(s)~* Blood collection

Intervention type: OTHER
Intervention: Sample collection
Description: * Optional nasal specimen(s)~* Blood collection
Study: NCT03428594

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CKD-11101

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NESP
Study: NCT00898079

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study: NCT04896164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin Lozenges
Description: Curcumin lozenges (each containing 100 mg of curcumin) will be given at a dose of 4 lozenges (total dose 400 mg curcumin) BD. Formulation is Solid Lipid Curcumin Particle (SLCP). Oral curcumin lozenges will be given from two days prior to receiving high dose chemotherapy till day+28 of transplant.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lozenges
Description: Placebo lozenges will be given from two days prior to receiving high dose chemotherapy till day+28 of transplant.
Study: NCT02665143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib and AML induction
Description: The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. In the phase I part, all patients will receive the combination with Nintedanib 200mg bid begun at day 8 and continued until end of cycle. If a significant incidence of dose limiting toxicities is demonstrated, Nintedanib will be given at a lower dose level (150mg bid).
Study: NCT02485808

Intervention type: OTHER
Intervention: None-observational
Description: For surgical patients, follow-up assessments will occur 3 and 12 months after the surgery. For medical patients, follow-up assessments will occur 3 and 12 months after the baseline assessment.

Intervention type: OTHER
Intervention: None-observational
Description: For surgical patients, follow-up assessments will occur 3 and 12 months after the surgery. For medical patients, follow-up assessments will occur 3 and 12 months after the baseline assessment.

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: One time MRI scanning session examining brain structure and function in a resting state and after water consumption.

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: One time MRI scanning session examining brain structure and function in a resting state and after water consumption.

Intervention type: OTHER
Intervention: Multimodal Automated Sensory Testing System
Description: Pressure pain thresholds will be assess using computer-controlled pressures delivered by a device called the Multimodal Automated Sensory Testing System (MAST) device on to the subjects thumbnail bed.

Intervention type: OTHER
Intervention: Multimodal Automated Sensory Testing System
Description: Pressure pain thresholds will be assess using computer-controlled pressures delivered by a device called the Multimodal Automated Sensory Testing System (MAST) device on to the subjects thumbnail bed.

Intervention type: OTHER
Intervention: Auditory Sensitivity Test
Description: Subjects' sensitivity to sound will be evaluated using a series of sounds delivered by a standard audiometer device.

Intervention type: OTHER
Intervention: Auditory Sensitivity Test
Description: Subjects' sensitivity to sound will be evaluated using a series of sounds delivered by a standard audiometer device.
Study: NCT02120443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ivWatch Model 400
Description: The ivWatch Model 400 monitored tissue at common IV sites over a 24 hour period.
Study: NCT00270959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational interviewing is designed to address alcohol and drug use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA-Approved Anti-Anxiety Medications
Description: Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Control
Description: Standard care control includes the usual treatment for injured trauma survivors.
Study: NCT03230149

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurements of the alpha-GAL enzyme activity
Description: Blotting paper blood tests in order to highlight an enzyme deficiency for hemizygous males with DBS kits in order to detect Fabry disease, with genetic confirmation if an abnormality is detected. For women genotyping is mandatory.
Study: NCT01370408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Prior to IV chemotherapy - ondansetron 8mg IV \& Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: Prior to IV chemotherapy - ondansetron 8mg IV \& Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Prior to IV chemotherapy - ondansetron 8mg IV \& Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV
Study: NCT04043871

Intervention type: DIAGNOSTIC_TEST
Intervention: Systolic blood pressure
Description: Systolic blood pressure measured by Foot-to-Apex Systolic Interval, conventional oscillometric measurement, and the auscultatory method
Study: NCT04883801

Intervention type: DIAGNOSTIC_TEST
Intervention: Reviewed clinical records and laboratory results
Description: Retrospectively reviewed clinical records and laboratory results

Intervention type: DIAGNOSTIC_TEST
Intervention: Reviewed clinical records and laboratory results
Description: Retrospectively reviewed clinical records and laboratory results
Study: NCT01130688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zileuton
Description: Imatinib combined with Zileuton
Study: NCT04525248

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic total colectomy + low resection of rectum
Description: Laparoscopic total colectomy + low resection of rectum

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic total colectomy + High resection of rectum
Description: Laparoscopic total colectomy + High resection of rectum
Study: NCT01200043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fructose restriction diet
Description: fruits and vegetables only
Study: NCT01471847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235 + Trastuzumab Phase l/Phase ll)
Description: Phase l: Patients will receive increasing doses of oral BEZ235 (BID) together with standard weekly trastuzumab at a fixed dose. BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established.~Phase ll: If randomized to the trastuzumab + BEZ235 arm, patients will receive standard weekly trastuzumab in combination with oral BEZ235 (BID) at the MTD or RP2D and will continue on study treatment until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met. They will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib + Capecitabine (Phase II)
Description: If randomized to the lapatinib + capecitabine treatment arm, patients will receive standard lapatinib plus capecitabine until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met.~Patients will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy). After progression, survival f-up will continue.~All patients participating in the Phase II part of the study will be required to have available archival or fresh tumor tissue for biomarker analysis prior to treatment start
Study: NCT01844219

Intervention type: PROCEDURE
Intervention: elective or emergency aortic surgery (including ascending, arch, descending thoracic aorta)
Study: NCT03588624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TearCare
Description: The TearCare procedure includes the delivery of thermal energy to the external surface of the eyelids for 15 minutes, immediately followed by manual expression of each eyelid.
Study: NCT01802697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IdeS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02796664

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginseng
Description: Korean Red Ginseng extract tablet (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months.
Study: NCT03444116

Intervention type: DIAGNOSTIC_TEST
Intervention: Motion Analysis
Description: Gait and Motion Analysis, comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)

Intervention type: DIAGNOSTIC_TEST
Intervention: Motion Analysis
Description: Gait and Motion Analysis, comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)

Intervention type: DIAGNOSTIC_TEST
Intervention: sterEOS Imaging of Lower Extremities
Description: Bi-planar imaging of the lower extremities to evaluate femoral anteversion and hip dysplasia and subluxation.

Intervention type: DIAGNOSTIC_TEST
Intervention: sterEOS Imaging of Lower Extremities
Description: Bi-planar imaging of the lower extremities to evaluate femoral anteversion and hip dysplasia and subluxation.

Intervention type: BEHAVIORAL
Intervention: Surveys
Description: 9 surveys assessing function, activity, participation, pain, quality of life, and treatment history.

Intervention type: BEHAVIORAL
Intervention: Surveys
Description: 9 surveys assessing function, activity, participation, pain, quality of life, and treatment history.
Study: NCT00543686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Intake of Montelukast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: Intake of Fluticasone
Study: NCT04182152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Description: Indocyanine green (ICG) was diluted with saline to 0.5mg/mL, and injected 0.6mL/site.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation bronchoscopy
Description: Electromagnetic navigation bronchoscopy (ENB) allows physicians to access peripheral lung nodules with high accuracy and provides a working channel for ICG injection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hook wire
Description: Hook wire is a puncture locating needle with a hook head that is about 1 cm in length and 30 cm metal wire behind. Through the puncture path planned based on CT scan, hook wire puncture percutaneously into the chest cavity to reach the lesion for localization.